Print Preview Area

Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
The Oncologist, 06/22/2012

Oizumi S et al. – Quality of life (QoL) was maintained much longer in patients treated with gefitinib than in patients treated with standard chemotherapy, indicating that gefitinib should be considered as the standard first–line therapy for advanced epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC) in spite of no survival advantage.

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Medical Student Jobs
@MDLinx Career Center
View the full listing of physician jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?

Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer The Oncologist, 06/22/2012

Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
The Oncologist, 06/22/2012